Agreement for Receiving M9 or M9/HTLV-IIIB Cell Line MAY 25 RECT

I have read and have agreed to adhere to the following guidelines for use of H9/HTLV-IIIB:

- 1. Use of H9 or H9/HTLV-IIIB will be limited to my immediate laboratory. I will not give it out without prior written approval from Dr. Gallo.
- 2. Work performed will be on a collaborative basis with Dr. Gallo, Dr. Popovic, Dr. Wong-Staal, and their colleagues (to be specified by them) for the specific purpose of studying expression of HTLV-LTR linked genes in these cells. No other experiments should be initiated with these cells without prior discussion with the above named people.
- 3. H9 or H9/HTLV-IIIB will not be used for commercial purposes. A U.S. Government (National Cancer Institute) patent is in effect.
- 4. Use of the H9/HTLV-111B line or virus produced from it will be according to U.S. Government recommendations (see attached). Work can be carried out in a biosafety level 2 facility if the equipment, techniques and access to the work area are maintained as biosafety level 3. Large scale production of the virus requires strict biosafety level 3 containment.
- Any operations using the infected cell outside of biocontainment will be after treatment such as gluteraldehyde fixation.

Signature	D a	te		 · · · · · ·
•			1	

(Please type or print name and address below)

Or. William A. Haseltine Harvard Univ. Med. Schl. Dana-Farber Cancer Inst. 44 Binney Street Ecston, Massachusetts 02115